552 related articles for article (PubMed ID: 17047383)
1. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
2. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
3. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
4. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
5. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
6. Biochemical evidence supporting the Cortina criteria.
von Werder K
J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
[TBL] [Abstract][Full Text] [Related]
7. Biochemical evidence in favor of revising Cortina criteria.
Webb SM; Sucunza N; Barahona MJ
J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
[TBL] [Abstract][Full Text] [Related]
8. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
9. Are there alternative tests for diagnosis of acromegaly?
Popovic V
J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
[TBL] [Abstract][Full Text] [Related]
10. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
11. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
12. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
13. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
15. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
16. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
Pokrajac A; Wark G; Ellis AR; Wear J; Wieringa GE; Trainer PJ
Clin Endocrinol (Oxf); 2007 Jul; 67(1):65-70. PubMed ID: 17437512
[TBL] [Abstract][Full Text] [Related]
17. Establishment of reference values for endocrine tests--part V: acromegaly.
Endert E; van Rooden M; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2006; 64(7):230-5. PubMed ID: 16929084
[TBL] [Abstract][Full Text] [Related]
18. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
19. IGF-I and mortality in patients with acromegaly.
Strasburger CJ
J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
[TBL] [Abstract][Full Text] [Related]
20. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
